HK1146242A1 - 使用黑素皮質素治療胰島素敏感性 - Google Patents

使用黑素皮質素治療胰島素敏感性

Info

Publication number
HK1146242A1
HK1146242A1 HK11100510.8A HK11100510A HK1146242A1 HK 1146242 A1 HK1146242 A1 HK 1146242A1 HK 11100510 A HK11100510 A HK 11100510A HK 1146242 A1 HK1146242 A1 HK 1146242A1
Authority
HK
Hong Kong
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
HK11100510.8A
Other languages
English (en)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1146242A1 publication Critical patent/HK1146242A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11100510.8A 2007-11-05 2011-01-19 使用黑素皮質素治療胰島素敏感性 HK1146242A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05
PCT/US2008/012490 WO2009061411A2 (en) 2007-11-05 2008-11-05 Use melanocortins to treat insulin sensitivity

Publications (1)

Publication Number Publication Date
HK1146242A1 true HK1146242A1 (zh) 2011-05-27

Family

ID=40626385

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11100510.8A HK1146242A1 (zh) 2007-11-05 2011-01-19 使用黑素皮質素治療胰島素敏感性
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Country Status (21)

Country Link
US (6) US9155777B2 (zh)
EP (2) EP2979703B1 (zh)
JP (3) JP2011502987A (zh)
KR (3) KR20150013339A (zh)
CN (2) CN101980717A (zh)
AR (1) AR069461A1 (zh)
AU (1) AU2008325194B2 (zh)
BR (1) BRPI0819188B1 (zh)
CA (2) CA2952095C (zh)
DK (1) DK2214693T3 (zh)
ES (2) ES2690556T3 (zh)
HK (3) HK1146242A1 (zh)
HU (1) HUE026842T2 (zh)
IL (2) IL205554A (zh)
NZ (1) NZ585131A (zh)
PL (1) PL2214693T3 (zh)
PT (2) PT2979703T (zh)
RU (1) RU2453328C2 (zh)
TR (1) TR201815292T4 (zh)
TW (1) TWI374030B (zh)
WO (1) WO2009061411A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689016C (en) * 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
RU2012108110A (ru) * 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии
HUE031856T2 (en) * 2009-08-31 2017-08-28 Tensive Controls Inc Stabilized melanocortin ligands
RU2548753C2 (ru) 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
MX2012005862A (es) 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
WO2012172433A2 (en) * 2011-06-14 2012-12-20 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
RU2019116003A (ru) 2013-03-15 2019-07-17 Ритм Фармасьютикалз, Инк. Фармацевтические композиции
CN118240012A (zh) 2013-03-15 2024-06-25 节奏制药公司 肽组合物
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CA3102603A1 (en) 2018-06-05 2019-12-12 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
US7034033B2 (en) * 2002-05-23 2006-04-25 Chiron Corporation Substituted quinazolinone compounds
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
JP2006521359A (ja) 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としての二環式ピペリジン誘導体
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
WO2006049933A2 (en) * 2004-10-29 2006-05-11 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
KR101232201B1 (ko) * 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
CA2689016C (en) * 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
RU2453328C2 (ru) * 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
RU2012108110A (ru) 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии

Also Published As

Publication number Publication date
JP5964767B2 (ja) 2016-08-03
IL205554A0 (en) 2010-12-30
CN103316345B (zh) 2016-05-18
EP2214693B1 (en) 2015-09-09
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
HUE026842T2 (en) 2016-08-29
EP2979703A1 (en) 2016-02-03
PL2214693T3 (pl) 2016-03-31
WO2009061411A2 (en) 2009-05-14
ES2690556T3 (es) 2018-11-21
CA2952095C (en) 2020-02-18
US20220339239A1 (en) 2022-10-27
NZ585131A (en) 2012-10-26
JP2015131827A (ja) 2015-07-23
JP2011502987A (ja) 2011-01-27
US9155777B2 (en) 2015-10-13
EP2214693A4 (en) 2012-04-11
IL205554A (en) 2017-01-31
US9827286B2 (en) 2017-11-28
AR069461A1 (es) 2010-01-27
TW200932258A (en) 2009-08-01
US9439943B2 (en) 2016-09-13
WO2009061411A3 (en) 2010-04-15
KR20150013339A (ko) 2015-02-04
US20190111105A1 (en) 2019-04-18
EP2979703B1 (en) 2018-07-18
EP2214693A2 (en) 2010-08-11
TWI374030B (en) 2012-10-11
PT2214693E (pt) 2015-12-07
US20180303899A1 (en) 2018-10-25
US20150366934A1 (en) 2015-12-24
BRPI0819188B1 (pt) 2021-06-22
DK2214693T3 (en) 2015-11-30
JP2013144690A (ja) 2013-07-25
KR20130065725A (ko) 2013-06-19
IL249998A0 (en) 2017-03-30
AU2008325194A1 (en) 2009-05-14
CN101980717A (zh) 2011-02-23
RU2010122897A (ru) 2011-12-20
PT2979703T (pt) 2018-10-31
TR201815292T4 (tr) 2018-11-21
KR101290623B1 (ko) 2013-08-07
HK1184692A1 (zh) 2014-01-30
ES2555522T3 (es) 2016-01-04
US20160354429A1 (en) 2016-12-08
CN103316345A (zh) 2013-09-25
BRPI0819188A2 (pt) 2015-09-01
CA2952095A1 (en) 2009-05-14
US20100311647A1 (en) 2010-12-09
CA2704651A1 (en) 2009-05-14
HK1221147A1 (zh) 2017-05-26
CA2704651C (en) 2017-03-07
AU2008325194B2 (en) 2012-04-19
IL249998B (en) 2018-07-31
RU2453328C2 (ru) 2012-06-20

Similar Documents

Publication Publication Date Title
HK1221147A1 (zh) 使用黑素皮質素治療胰島素敏感性
IL213596A0 (en) Heterocyclic compounds and methods of use
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (zh) 化合物和使用方法
HK1154054A1 (en) Predictors of patient response to treatment with egf receptor inhibitors
IL208354A0 (en) Methods of treatment
GB0707750D0 (en) Treatment of organic matter
HK1160925A1 (zh) 組織蛋白酶 的用途
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB2448592B (en) Improvements to coffins
EP2470020A4 (en) BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
GB0723100D0 (en) Treatment of HFnEF
EP2066171A4 (en) ADMINISTERING A TREATMENT SUBSTANCE TO POROUS ELEMENTS
HK1156250A1 (zh) 阿帕地松單位劑量
GB0814296D0 (en) Improvements to coffins
GB0802903D0 (en) Treatment of diabetes
GB0801958D0 (en) Improvements relating to electro-optical sensors and their use
IL190834A0 (en) Improvements to bandages
GB0816217D0 (en) Treatment of hepatitis C
HU0800656D0 (en) Effective use of tea-composition
GB0809469D0 (en) Improvements relating to body jewelry
FI20080503A0 (fi) MSM-elementtien pintakäsittely
GB0717139D0 (en) Treatment of hepatitis C
GB0719334D0 (en) Improvements relating to electro-optical sensors and their use